Coherus Biosciences Inc (NASDAQ:CHRS) CFO Jean-Frederic Viret sold 3,159 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $20.44, for a total transaction of $64,569.96. Following the completion of the transaction, the chief financial officer now owns 11,672 shares of the company’s stock, valued at $238,575.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Jean-Frederic Viret also recently made the following trade(s):
- On Monday, September 23rd, Jean-Frederic Viret sold 740 shares of Coherus Biosciences stock. The stock was sold at an average price of $21.78, for a total transaction of $16,117.20.
- On Wednesday, August 21st, Jean-Frederic Viret sold 6,318 shares of Coherus Biosciences stock. The stock was sold at an average price of $21.71, for a total transaction of $137,163.78.
- On Monday, August 19th, Jean-Frederic Viret sold 3,000 shares of Coherus Biosciences stock. The stock was sold at an average price of $19.04, for a total transaction of $57,120.00.
Shares of Coherus Biosciences stock opened at $20.48 on Friday. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -6.36 and a beta of 2.96. The firm’s 50-day moving average is $20.75 and its 200 day moving average is $18.28. Coherus Biosciences Inc has a 1 year low of $8.32 and a 1 year high of $23.91.
Coherus Biosciences (NASDAQ:CHRS) last posted its earnings results on Thursday, August 1st. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.40. The company had revenue of $83.43 million for the quarter, compared to the consensus estimate of $81.05 million. Research analysts anticipate that Coherus Biosciences Inc will post 0.89 earnings per share for the current fiscal year.
Several research analysts have commented on CHRS shares. BidaskClub downgraded shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, September 6th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price (up from $28.00) on shares of Coherus Biosciences in a research note on Friday, August 2nd. Maxim Group reaffirmed a “buy” rating and issued a $27.00 target price (up from $25.00) on shares of Coherus Biosciences in a research note on Friday, August 2nd. ValuEngine downgraded shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Finally, Barclays set a $31.00 price objective on shares of Coherus Biosciences and gave the company a “buy” rating in a research report on Monday, August 12th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $31.38.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CHRS. Chartwell Investment Partners LLC purchased a new position in shares of Coherus Biosciences during the second quarter valued at $3,449,000. United Services Automobile Association grew its stake in Coherus Biosciences by 0.9% in the second quarter. United Services Automobile Association now owns 217,216 shares of the biotechnology company’s stock valued at $4,800,000 after purchasing an additional 1,950 shares during the last quarter. Nuveen Asset Management LLC purchased a new position in Coherus Biosciences in the second quarter valued at about $25,695,000. Jane Street Group LLC acquired a new stake in Coherus Biosciences in the second quarter worth about $424,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in Coherus Biosciences by 83.7% in the second quarter. Cubist Systematic Strategies LLC now owns 27,814 shares of the biotechnology company’s stock worth $615,000 after acquiring an additional 12,671 shares in the last quarter. 95.19% of the stock is owned by hedge funds and other institutional investors.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Recommended Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.